Results 101 to 110 of about 19,474 (223)

GD2-Specific CAR T Cells Demonstrate Potent and Targeted Anti-Tumor Efficacy Against Melanoma In Vitro and In Vivo

Frontiers in Bioscience-Landmark
Background: Disialoganglioside (GD2) is a tumor-associated antigen that is highly expressed in various neuroectodermal cancers, including melanoma.
Julia Philippova, Julia Shevchenko, Alaa Alsalloum, Marina Fisher, Saleh Alrhmoun, Roman Perik-Zavodskii, Olga Perik-Zavodskaia, Julia Lopatnikova, Vasily Kurilin, Marina Volynets, Evgenii Zavjalov, Olga Solovieva, Hiroshi Shiku, Sergey Sennikov   +13 more
doaj   +1 more source

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

Journal for ImmunoTherapy of Cancer
Background The survival benefit observed in children with neuroblastoma (NB) and minimal residual disease who received treatment with anti-GD2 monoclonal antibodies prompted our investigation into the safety and potential clinical benefits of anti-CD3 ...
M. Yankelevich, A. Thakur, S. Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Dana L. Schalk, Amy Schienshang, Sarah A. Whitaker, Katie Rea, Daniel W. Lee, Qin Liu, A. Shields, Nai-Kong V. Cheung, Lawrence G. Lum   +14 more
semanticscholar   +1 more source

Beauty in the Eye of AI: Aligning LLMs and Vision Models with Human Aesthetics in Network Visualization

Computer Graphics Forum, EarlyView.
Abstract Network visualization has traditionally relied on heuristic metrics, such as stress, under the assumption that optimizing them leads to aesthetic and informative layouts. However, no single metric consistently produces the most effective results.
X. Li, P. Zhang, X. Wang, H. Shen, Y. Hu
wiley   +1 more source

Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.

Clinical Cancer Research
PURPOSE Cytokine-engineering of chimeric antigen receptor-redirected T cells (CAR T cells) is a promising principle to overcome the limited activity of canonical CAR T cells against solid cancers.
Lena Fischer-Riepe, S. Kailayangiri, Katharina Zimmermann, Rita Pfeifer, M. Aigner, B. Altvater, S. Kretschmann, S. Völkl, J. Hartley, Celine Dreger, Katja Petry, A. Bosio, Angelika von Döllen, Wolfgang Hartmann, Holger N. Lode, Dennis Görlich, A. Mackensen, M. Jungblut, Axel Schambach, Hinrich Abken, C. Rossig   +20 more
semanticscholar   +1 more source

Clues of ancient incomplete lineage sorting during bivalve evolution undermine support for Heterodonta

Cladistics, EarlyView.
Abstract A long‐standing challenge in phylogenomics has been the resolution of relationships originated from ancient radiations. In these cases, phenomena such as incomplete lineage sorting can increase the support for conflicting resolutions. Most of the diversity in the Class Bivalvia originated during an Ordovician radiation; indeed, several deep ...
Alessandro Formaggioni, Takeshi Takeuchi, Mayuko Hamada, Kazuhiro Saito, Tatsuya Sakamoto, Noriyuki Satoh, Federico Plazzi, Marco Passamonti   +7 more
wiley   +1 more source

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

Nature Communications
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment ...
Guillem Pascual-Pasto, Brendan McIntyre, Margaret G. Hines, Anna M. Giudice, Laura Garcia-Gerique, Jennifer Hoffmann, Pamela Mishra, Stephanie Matlaga, Simona Lombardi, Rawan Shraim, Patrick M. Schürch, Mark Yarmarkovich, Ted J. Hofmann, Fatemeh Alikarami, Daniel Martinez, Matthew Tsang, Luis Gil-de-Gómez, Timothy T. Spear, Kathrin M. Bernt, Adam J. Wolpaw, Dimiter S. Dimitrov, Wei Li, Kristopher R. Bosse   +22 more
doaj   +1 more source

Combining TAG‐72CAR with anti‐MUC16CAR improves the potency of ovarian cancer treatment

The FEBS Journal, EarlyView.
Tz‐KBBCAR, a combinatorial CAR targeting MUC16 and TAG‐72, enhances the precision of ovarian cancer immunotherapy. By requiring both tumour antigens for full activation, Tz‐KBBCAR was designed to eliminate MUC16+/TAG‐72+ cancer cells, while sparing MUC16+/TAG‐72‐ healthy cells.
Alicia Villatoro, Aurore Dougé, Klara Krpina, Lea‐Marie Schmitz, Christopher Forcados, Fatemeh Kaveh, Andrea Estrella Arias‐Díaz, Pascal Gelebart, Emmet McCormack, Renata Stripecke, Miguel Abal, Ben Davidson, Else Marit Inderberg, Sébastien Wälchli   +13 more
wiley   +1 more source

Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. [PDF]

, 2016
Neuroectodermal tumours are characterized by aberrant processing of disialogangliosides concomitant with high expression of GD2 or GD3 on cell surfaces. Antibodies targeting GD2 are already in clinical use for therapy of neuroblastoma, a solid tumour of ...
Wolfgang Sauerwein, Brandau, Wolfgang, Stefan P Müller, Wolfgang Brandau, Vogt, Sebastian, Schramm, Alexander, Robin Reichel, Jan Müller, Mueller, Stefan P., Alexander Schramm, Sauerwein, Wolfgang, Reichel, Robin, Sebastian Vogt, Eggert, Angelika, Mueller, Jan, Angelika Eggert   +15 more
core   +2 more sources

Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence

bioRxiv
Manufacturing Chimeric Antigen Receptor (CAR) T cell therapies is complex, with limited understanding of how media composition impact T-cell phenotypes. CRISPR/Cas9 ribonucleoproteins can precisely insert a CAR sequence while disrupting the endogenous T ...
D. Cappabianca, D. Pham, M. Forsberg, Madison Bugel, Anna Tommasi, Anthony C. Lauer, J. Vidugiriene, B. Hrdlicka, Alexandria McHale, Q. Sodji, M. Skala, C. Capitini, Krishanu Saha   +12 more
semanticscholar   +1 more source

A guide to studying tumour‐T‐cell interactions using in vitro coculture assays

The FEBS Journal, EarlyView.
In vitro tumour‐T‐cell coculture systems provide a controlled way to study how T cells recognise and kill tumour cells. Different tumour models can be combined with antigen‐specific TCR or CAR T cells, while antigen presentation, cytokines, drugs and tumour genetics can be manipulated.
Nooshin Khoshdoozmasouleh, Conor J. Kearney   +1 more
wiley   +1 more source